Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +65.40% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.21 | N/A | +65.40% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management highlighted the positive EPS surprise as a sign of progress. They remain focused on advancing their clinical programs.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized ongoing efforts in their drug development pipeline.
Protagonist Therapeutics reported a better-than-expected EPS for the quarter, which contributed to a 5.15% increase in stock price. The lack of revenue data leaves some uncertainty, but the positive EPS surprise indicates potential operational improvements. Investors may view this as a step in the right direction for the company's future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ARISTA NETWORKS INC
Nov 2, 2020